Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID-19 Pandemic.


Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
04 2021
Historique:
received: 07 09 2020
accepted: 22 01 2021
pubmed: 5 2 2021
medline: 28 4 2021
entrez: 4 2 2021
Statut: ppublish

Résumé

Triage procedures have been implemented to limit hospital access and minimize infection risk among patients with cancer during the coronavirus disease (COVID-19) outbreak. In the absence of prospective evidence, we aimed to evaluate the predictive performance of a triage system in the oncological setting. This retrospective cohort study analyzes hospital admissions to the oncology and hematology department of Udine, Italy, during the COVID-19 pandemic (March 30 to April 30, 2020). A total of 3,923 triage procedures were performed, and data of 1,363 individual patients were reviewed. A self-report triage questionnaire identified 6% of triage-positive procedures, with a sensitivity of 66.7% (95% confidence interval [CI], 43.0%-85.4%), a specificity of 94.3% (95% CI, 93.5%-95.0%), and a positive predictive value of 5.9% (95% CI, 4.3%-8.0%) for the identification of patients who were not admitted to the hospital after medical review. Patients with thoracic cancer (odds ratio [OR], 1.69; 95% CI, 1.13-2.53, p = .01), younger age (OR, 1.52; 95% CI, 1.15-2.01, p < .01), and body temperature at admission ≥37°C (OR, 9.52; 95% CI, 5.44-16.6, p < .0001) had increased risk of positive triage. Direct hospital access was warranted to 93.5% of cases, a further 6% was accepted after medical evaluation, whereas 0.5% was refused at admission. A self-report questionnaire has a low positive predictive value to triage patients with cancer and suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptoms. Differential diagnosis with tumor- or treatment-related symptoms is always required to avoid unnecessary treatment delays. Body temperature measurement improves the triage process's overall sensitivity, and widespread SARS-CoV-2 testing should be implemented to identify asymptomatic carriers. This is the first study to provide data on the predictive performance of a triage system in the oncological setting during the coronavirus disease outbreak. A questionnaire-based triage has a low positive predictive value to triage patients with cancer and suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptoms, and a differential diagnosis with tumor- or treatment-related symptoms is mandatory to avoid unnecessary treatment delays. Consequently, adequate recourses should be reallocated for a triage implementation in the oncological setting. Of note, body temperature measurement improves the overall sensitivity of the triage process, and widespread testing for SARS-CoV-2 infection should be implemented to identify asymptomatic carriers.

Sections du résumé

BACKGROUND
Triage procedures have been implemented to limit hospital access and minimize infection risk among patients with cancer during the coronavirus disease (COVID-19) outbreak. In the absence of prospective evidence, we aimed to evaluate the predictive performance of a triage system in the oncological setting.
MATERIALS AND METHODS
This retrospective cohort study analyzes hospital admissions to the oncology and hematology department of Udine, Italy, during the COVID-19 pandemic (March 30 to April 30, 2020). A total of 3,923 triage procedures were performed, and data of 1,363 individual patients were reviewed.
RESULTS
A self-report triage questionnaire identified 6% of triage-positive procedures, with a sensitivity of 66.7% (95% confidence interval [CI], 43.0%-85.4%), a specificity of 94.3% (95% CI, 93.5%-95.0%), and a positive predictive value of 5.9% (95% CI, 4.3%-8.0%) for the identification of patients who were not admitted to the hospital after medical review. Patients with thoracic cancer (odds ratio [OR], 1.69; 95% CI, 1.13-2.53, p = .01), younger age (OR, 1.52; 95% CI, 1.15-2.01, p < .01), and body temperature at admission ≥37°C (OR, 9.52; 95% CI, 5.44-16.6, p < .0001) had increased risk of positive triage. Direct hospital access was warranted to 93.5% of cases, a further 6% was accepted after medical evaluation, whereas 0.5% was refused at admission.
CONCLUSION
A self-report questionnaire has a low positive predictive value to triage patients with cancer and suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptoms. Differential diagnosis with tumor- or treatment-related symptoms is always required to avoid unnecessary treatment delays. Body temperature measurement improves the triage process's overall sensitivity, and widespread SARS-CoV-2 testing should be implemented to identify asymptomatic carriers.
IMPLICATIONS FOR PRACTICE
This is the first study to provide data on the predictive performance of a triage system in the oncological setting during the coronavirus disease outbreak. A questionnaire-based triage has a low positive predictive value to triage patients with cancer and suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptoms, and a differential diagnosis with tumor- or treatment-related symptoms is mandatory to avoid unnecessary treatment delays. Consequently, adequate recourses should be reallocated for a triage implementation in the oncological setting. Of note, body temperature measurement improves the overall sensitivity of the triage process, and widespread testing for SARS-CoV-2 infection should be implemented to identify asymptomatic carriers.

Identifiants

pubmed: 33539583
doi: 10.1002/onco.13706
pmc: PMC8014855
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e694-e703

Informations de copyright

© 2021 AlphaMed Press.

Références

Int J Clin Pract. 2010 Feb;64(3):316-21
pubmed: 20456171
Front Oncol. 2020 Apr 22;10:665
pubmed: 32391282
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Ann Oncol. 2020 May;31(5):553-555
pubmed: 32201224
JCO Oncol Pract. 2020 Aug;16(8):467-482
pubmed: 32401686
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Cancers Head Neck. 2020 May 6;5:7
pubmed: 32391172
Support Care Cancer. 2021 Apr;29(4):2057-2062
pubmed: 32856214
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
J Clin Oncol. 2020 Jul 1;38(19):2201-2205
pubmed: 32343643
Nat Rev Clin Oncol. 2020 May;17(5):268-270
pubmed: 32242095
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Ann Intern Med. 2020 May 5;172(9):619-620
pubmed: 32160299
N Engl J Med. 2020 Aug 20;383(8):779-786
pubmed: 32558484
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
ESMO Open. 2020 Mar;5(2):
pubmed: 32229501
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Nat Cancer. 2020 Jun;1(6):565-567
pubmed: 35121972
Oncologist. 2020 Jun;25(6):463-467
pubmed: 32298029

Auteurs

Gianpiero Fasola (G)

Department of Oncology, Santa Maria della Misericordia Hospital, Udine, Italy.

Giacomo Pelizzari (G)

Department of Oncology, Santa Maria della Misericordia Hospital, Udine, Italy.

Diego Zara (D)

Department of Oncology, Santa Maria della Misericordia Hospital, Udine, Italy.

Giada Targato (G)

Department of Oncology, Santa Maria della Misericordia Hospital, Udine, Italy.

Giuseppe Petruzzellis (G)

Department of Hematology, Santa Maria della Misericordia Hospital, Udine, Italy.

Alessandro Marco Minisini (AM)

Department of Oncology, Santa Maria della Misericordia Hospital, Udine, Italy.

Alessandra Bin (A)

Department of Oncology, Santa Maria della Misericordia Hospital, Udine, Italy.

Raffaela Donato (R)

Department of Oncology, Santa Maria della Misericordia Hospital, Udine, Italy.

Mauro Mansutti (M)

Department of Oncology, Santa Maria della Misericordia Hospital, Udine, Italy.

Chiara Comuzzi (C)

Department of Hematology, Santa Maria della Misericordia Hospital, Udine, Italy.

Anna Candoni (A)

Department of Hematology, Santa Maria della Misericordia Hospital, Udine, Italy.

Alessandra Sperotto (A)

Department of Hematology, Santa Maria della Misericordia Hospital, Udine, Italy.

Renato Fanin (R)

Department of Hematology, Santa Maria della Misericordia Hospital, Udine, Italy.
Department of Medicine, University of Udine, Udine, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH